MétaCan
Menu
Back to cohort
Record W4225678126 · doi:10.1093/ehjcvp/pvac023

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

2022· article· en· W4225678126 on OpenAlexaff
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Jessica Tyrwitt, Keith A.A. Fox, Eva Muehlhofer, Christoph Neumann, Christoph Tasto, Shrikant I. Bangdiwala, Rafael Díaz, Marco Alings, Gilles R. Dagenais, Darryl P. Leong, Eva Lonn, Álvaro Avezum, Leopoldo Soares Piegas, Petr Widimský, Alexander Parkhomenko, Deepak L. Bhatt, Kelley R. Branch, Jeffrey L. Probstfield, Patricio López‐Jaramillo, Lars Rydén, Nana Pogosova, Katalin Keltai, Mátyás Keltai, Georg Ertl, Stefan Störk, Antonio L Dans, Fernando Laņas, Yan Liang, Jun Zhu, Christian Torp‐Pedersen, Aldo P. Maggioni, Patrick Commerford, Tomasz J. Guzik, Thomas Vanassche, Peter Verhamme, Martin O’Donnell, Andrew M. Tonkin, George Varigos, Dragoş Vinereanu, Camillo Felix, Jae‐Hyung Kim, Khairul Shafiq Ibrahim, Basil S. Lewis, Kaj Metsärinne, Victor Aboyans, Philippe Gabríel Steg, Masatsugu Hori, Ajay K. Kakkar, Sonia S. Anand, André Lamy, Mukul Sharma, Salim Yusuf

Bibliographic record

VenueEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2022
Typearticle
Languageen
FieldMedicine
TopicAtrial Fibrillation Management and Outcomes
Canadian institutionsInstitut universitaire de cardiologie et de pneumologie de QuébecMcMaster UniversityPopulation Health Research InstituteHamilton Health SciencesHamilton General Hospital
FundersJanssen PharmaceuticalsIdorsia PharmaceuticalsKU LeuvenSanofiBayer HealthCareBristol-Myers SquibbCSL BehringMerckBayerServierPfizerBoehringer Ingelheim
KeywordsMedicineRivaroxabanAspirinCoronary artery diseaseInternal medicineMyocardial infarctionStroke (engine)Randomized controlled trialHazard ratioConfidence intervalWarfarinSurgeryCardiologyAtrial fibrillation

Abstract

fetched live from OpenAlex

AIMS: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE). METHODS AND RESULTS: Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1-1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11-2.61], mortality 1.87 (1.65-2.10), stroke 0.62 (0.50-0.76), and MI 1.02 (0.86-1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86-1.19) and 2.49 (2.24-2.75), compared with 1.67 (1.48-1.87) and 5.11 (95% CI 4.77-5.47), respectively, during the randomized treatment phase with the combination. CONCLUSION: In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.067
Threshold uncertainty score0.321

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.063
GPT teacher head0.332
Teacher spread0.268 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations23
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart Journal - Cardiovascular PharmacotherapySame topicAtrial Fibrillation Management and OutcomesFrench-language works237,207